Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 19;18(1):13.
doi: 10.1186/s12978-021-01073-3.

Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies

Philippe Merviel  1 , Pandora James  2 , Sarah Bouée  2 , Mathilde Le Guillou  2 , Camille Rince  2 , Charlotte Nachtergaele  3 , Véronique Kerlan  3
Affiliations
Review

Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies

Philippe Merviel et al. Reprod Health. .

Abstract

Polycystic ovary syndrome (PCOS) is marked in 30 to 40% by insulin resistance and hyperandrogenism. Myo-inositol (MI) increases insulin sensitivity, decreases hyperandrogenism and improves the menstrual cycle. Its effect during assisted reproductive technologies (ART) has been studied by many authors. We conducted a review of the literature on the impact of MI administration in PCOS women in assisted reproductive technologies. Myo-inositol is effective in normalizing ovarian function, improving oocyte and embryo quality in PCOS, however further evaluations by large multicentre randomized controlled trials are needed to assess the clinical pregnancy and live birth rates in ART.

Keywords: Embryo quality; In vitro fertilization; Intracytoplasmic sperm injection (IVF-ICSI); Myo-inositol; Polycystic ovary syndrome (PCOS); Pregnancy.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in relation to the present study.

Figures

Fig. 1
Fig. 1
Roles of myo-inositol (MI) in the ovary (original figure from the author, after review of patho-physiologic effects of MI, DCI and others hormones on ovarian cells). MI: myo-inositol; DCI: D-chiro-inositol; (40:1): MI/DCI ratio; LHR: LH receptor; PKA: protein kinase A; P: progesterone; T: testosterone; INs: insulin; InsR: insulin receptor; bm: basalis membrane; PIP: phospho inositide phosphate; IP3: inositide triphosphate; AMH: anti-Müllerian hormone; E2: estradiol; + : stimulating effect
See this image and copyright information in PMC

References

    1. Merviel P, Bouée S, Ménard M, Le Martelot MT, Roche S, Lelièvre C, et al. Which ovarian stimulation to which women: the polycystic ovary syndrome (PCOS) Gynecol Obstet Fertil Senol. 2017;45:623–631. - PubMed
    1. Chiu TTY, Rogers MS, Law ELK, Britton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF : relationship with oocyte quality. Hum Reprod. 2002;17:1591–1596. doi: 10.1093/humrep/17.6.1591. - DOI - PubMed
    1. Lagana AS, Garzon S, Casarin J, Franchi M, Ghazzi F. Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology-based approach. Trends Endocrinol Metab. 2018;29:768–780. doi: 10.1016/j.tem.2018.09.001. - DOI - PubMed
    1. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double-blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11:347–354. - PubMed
    1. Larner J. D-chiro-inositol – its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002;3:47–60. doi: 10.1080/15604280212528. - DOI - PMC - PubMed